Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN

AIMS: Chronic kidney disease (CKD) in heart failure (HF) increases the risk of hyperkalaemia (HK), limiting angiotensin‐converting enzyme inhibitor (ACE‐I) or angiotensin receptor blocker (ARB) use. Patiromer is a sodium‐free, non‐absorbed potassium binder approved for HK treatment. We retrospective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESC Heart Fail
Main Authors: Pitt, Bertram, Bakris, George L., Weir, Matthew R., Freeman, Mason W., Lainscak, Mitja, Mayo, Martha R., Garza, Dahlia, Zawadzki, Rezi, Berman, Lance, Bushinsky, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073017/
https://ncbi.nlm.nih.gov/pubmed/29767459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12292
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados